Article thumbnail

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy

By Paul Richardson, Constantine Mitsiades, Jacob Laubach, Robert Schlossman, Irene Ghobrial, Teru Hideshima, Nikhil Munshi and Kenneth Anderson
Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2899783
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A budget impact model comparing resource utilization of four approved therapies for multiple myeloma (MM)
  2. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.
  3. A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy.
  4. A phase 2 study of bortezomib in relapsed, refractory myeloma.
  5. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
  6. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol.
  7. (1996). A prognostic index for multiple myeloma.
  8. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
  9. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract].
  10. (2008). Accessed
  11. (2007). An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma.
  12. and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/ refractory multiple myeloma (MM): preliminary results of a phase II study [abstract].
  13. ASH/FDA Panel on Clinical Endpoints in Multiple Myeloma. Clinically relevant end points and new drug approvals for myeloma.
  14. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
  15. Atypical serum immunofixation pattern (ASIP) development during induction therapy with BiRD for newly diagnosed multiple myeloma correlates with a high rate of complete remission [abstract].
  16. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
  17. (2006). Black box warning on lenalidomide-associated venous thromboembolism (VTE) in off-label setting: A preemptive and unusual safety initiative [abstract]. J Clin Oncol.
  18. Bortezomib continues to demonstrate superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: updated results of the APEX trial [abstract].
  19. (2005). Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res.
  20. (2008). Cancer Institute. Surveillance Epidemiology and End Results (SEER).
  21. Cancer Society). Detailed Guide: Multiple Myeloma.
  22. (2008). Cancer statistics,
  23. Clinical and biologic implications of recurrent genomic aberrations in myeloma.
  24. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
  25. (2009). Comprehensive Cancer Network®). NCCN Clinical Practice Guidelines in Oncology™.
  26. (1998). Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br
  27. Current treatment strategies for multiple myeloma. Clin Lymphoma Myeloma. 2007;7(Suppl 4):S139–S144.
  28. Dexamethasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM-009/010 sub-analysis) [abstract].
  29. (1999). Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.
  30. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
  31. ECOG performance status affects efficacy, but not safety, of lenalidomide/dexamethasone in relapsed/refractory multiple myeloma (MM009/010 sub-analysis) [abstract].
  32. Economic evaluation of lenalidomide for the treatment of multiple myeloma in Wales in patients who have received at least one prior therapy [abstract].
  33. (2008). Effect of lenalidomidebased regimens on bone remodeling in patients with relapsed/ refractory multiple myeloma [abstract]. Haematologica.
  34. Effect on survival of lenalidomide and dexamethasone associated deep vein thrombosis (DVT) in relapsed multiple myeloma patients [abstract].
  35. Efficacy of single-agent bortezomib vs single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.
  36. (2006). Emerging role of novel combinations for induction therapy in multiple myeloma. Clin Lymphoma Myeloma.
  37. (2008). Estimating direct costs of care for patients with relapsed or refractory multiple myeloma in French hospitals [abstract]. J Clin Oncol.
  38. Evaluation of five staging systems in 470 patients with multiple myeloma.
  39. Expanded Access Program (EAP) for lenalidomide (Revlimid®) plus dexamethasone in over 1400 subjects with relapsed or refractory multiple myeloma [abstract].
  40. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
  41. (2008). Final analysis of MM-014: single-agent lenalidomide in patients with relapsed and refractory multiple myeloma [abstract]. J Clin Oncol.
  42. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res.
  43. GIMEMA – Italian Multiple Myeloma Network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA – Italian Multiple Myeloma Network.
  44. (2008). High incidence of diarrhea in patients on long term therapy with lenalidomide and dexamethasone for multiple myeloma [abstract]. J Clin Oncol.
  45. High incidence of thrombotic events observed in patients receiving lenalidomide (L) + dexamethasone (D) (LD) as first-line therapy for multiple myeloma (MM) without aspirin (ASA) prophylaxis [abstract].
  46. IMiDs: a novel class of immunomodulators.
  47. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
  48. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.
  49. (2008). Impact of lenalidomide therapy on stem cell mobilization in myeloma [abstract]. J Clin Oncol.
  50. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
  51. (2006). Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation. Hematology Am Soc Hematol Educ Program.
  52. (1993). Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I – a randomized study. Myeloma Group of Western Sweden.
  53. Inter-Groupe Francophone du Myélome (IFM). Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.
  54. Intergroupe Francophone du Myélome. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.
  55. International Myeloma Working Group International uniform response criteria for multiple myeloma.
  56. International staging system for multiple myeloma.
  57. Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologicche dell’Adulto. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
  58. Lenalidomide – the phoenix rises.
  59. (2006). Lenalidomide (L) in combination with dexamethasone (D) improves survival and time to progression in elderly patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM) [abstract].
  60. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.
  61. Lenalidomide (Revlimid®) +/- corticosteroids in elderly patients with relapsed/refractory multiple myeloma [abstract].
  62. (2007). Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res.
  63. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy.
  64. (2008). Lenalidomide and stem cell collection in patients with multiple myeloma [abstract]. J Clin Oncol.
  65. Lenalidomide and thalidomide: mechanisms of action – similarities and differences. Semin Hematol.
  66. Lenalidomide in combination with dexamethasone is more effective than dexamethasone at first relapse in relapsed multiple myeloma [abstract].
  67. Lenalidomide overcomes poor prognosis conferred by del13q and t(4;14) but not del17p13 in multiple myeloma: results of the Canadian MM016 trial [abstract].
  68. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial [abstract].
  69. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
  70. Lenalidomide/dexamethasone improves response and prolongs time to progression, even in patients with IgA multiple myeloma: a sub-analysis of the MM-009/010 studies [abstract].
  71. (2008). Long-term responses observed with lenalidomide therapy for patients with relapsed or refractory multiple myeloma [abstract]. J Clin Oncol.
  72. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin
  73. low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma [abstract].
  74. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.
  75. Maintenance therapy in multiple myeloma.
  76. (2003). Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol.
  77. (2007). Medicines Agency. Scientific Discussion,
  78. melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma [abstract].
  79. (2008). MM-009 and MM-010 Investigators. The efficacy and safety of lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma patients with impaired renal function [abstract]. J Clin Oncol.
  80. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
  81. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
  82. (2002). Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer.
  83. Multiple myeloma.
  84. (2008). Myeloma Research Foundation. Multiple myeloma: disease overview.
  85. Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol.
  86. (2005). New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals. Clin Lymphoma Myeloma.
  87. New drugs for myeloma.
  88. (2004). New drugs for treatment of multiple myeloma. Lancet Oncol.
  89. (2005). Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res.
  90. (2008). Overall survival with dexamethasone in phase III multiple myeloma trials after adjustment for cross-over to lenalidomide [abstract]. Haematologica.
  91. Phase I trial of oral vorinostat in combination with bortezomib in advanced multiple myeloma [abstract]. Haematologica. 2008;93(Suppl 1). Abstract 0640.
  92. Phase I trial of vorinostat plus bortezomib (Bort) in relapsed and refractory multiple myeloma (MM) patients (pts) [abstract].
  93. (2008). Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM) [abstract]. J Clin Oncol.
  94. Phase II trial of bevacizumab combined with low dose dexamethasone and lenalidomide (Bev/Rev/Dex) for relapsed or refractory myeloma (MM) [abstract].
  95. Phase II trial of lenalidomide, cyclophosphamide, and dexamethasone (CRd) for newly diagnosed myeloma [abstract].
  96. (1995). Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.
  97. prednisone and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia/ thrombocytopenia and time to event results [abstract].
  98. Pretreatment with thalidomide and bortezomib does not influence response to lenalidomide in relapsed myeloma. Preliminary results from patients included in Dutch compassionate need programme [abstract].
  99. (1999). Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors.
  100. (1999). Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am.
  101. Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma [abstract].
  102. RADAR update on thalidomide (Thal)- and lenalidomide (Len)-associated venous thromboembolism (VTE): safety concerns persist for multiple myeloma (MM) despite FDA approvals in this setting [abstract].
  103. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
  104. Relapsed/refractory multiple myeloma patients treated with lenalidomide/dexamethasone who achieve a complete or near complete response have longer overall survival and time to progression compared with patients achieving a partial response [abstract].
  105. (2007). Relevant prognostic features of multiple myeloma and the new International Staging System. Leuk Lymphoma.
  106. Results of a phase I/II trial of Deutsche Studiengruppe Multiples Myelom, showing efficacy and safety of RAD regimen (Revlimid®, Adriamycin®, dexamethasone) in relapsed/refractory multiple myeloma [abstract].
  107. (2008). Revlimid (lenalidomide) Prescribing information.
  108. (2009). Revlimid® Prescribing Information.
  109. (2008). Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study [abstract]. J Clin Oncol.
  110. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
  111. (2004). Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant.
  112. (2008). Stem cell mobilization with cylophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant.
  113. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232 [abstract].
  114. (2003). Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma.
  115. (2001). Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol.
  116. (2005). Thalidomide and dexamethasone: therapy for multiple myeloma. Expert Rev Anticancer Ther.
  117. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
  118. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
  119. Thalidomide and lenalidomide in the treatment of multiple myeloma.
  120. (2005). Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival. Ann Hematol.
  121. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin
  122. (2004). The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets.
  123. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/ osteoprotegerin ratio.
  124. The efficacy and toxicity of the RAD regimen (Revlimid®, Adriamycin®, dexamethasone) in relapsed and refractory multiple myeloma – a phase I/II trial of “Deutsche Studiengruppe Multiples Myelom” [abstract].
  125. The evolution of thalidomide and its IMiD derivatives as anticancer agents.
  126. (2007). The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opin Pharmacother.
  127. (2007). The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program.
  128. (2007). Towards a new age in the treatment of multiple myeloma. Ann Hematol.
  129. (2005). Treatment of myeloma in patients not eligible for transplantation. Curr Treat Options Oncol.
  130. (2005). UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma
  131. (2007). Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer.
  132. (1997). Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.
  133. VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.